RE:RE:RE:RVX Analyst Report, CDN$5.85 target http://www.resverloHi Jkj.
I have just read the full report and I feel it is exactly what I and many other shareholders have been asking for years.
- It is very clear and you don't need to be a scientist to read it.
- It explains the epigenetic mechanisms and where rvx--208 fits plus the future epigenetic applications.
- It reflects what the science posters have been saying about the power of rvx-208 and it reflects how advanced RVX (and hence Zenith) is.
- The valuation assumptions are very clear and external case studies have been used to support the valuations.
I believe the valuation is extremely conservative but they have taken a disciplined approach which provides a clear perspective of how underestimated the current share price is.
I hope the scientists weigh in on this.
I feel that everyone should take an hour and read this report and gain an understanding about RVX's achievements. It bothers me that sometimes people suggest that RVX is a penny stock. RVX is anything BUT a penny stock. While they are not generating revenue at this stage their capabilities are growing exponentially. There are many companies like Twitter that are valued in the billions but do not generate any profit.
Below are some sections of the report.
GLTA Things are looking fantastic.
Cheers
Toinv :)
Key Value Assumptions We value RVX-208, and thereby Resverlogix as a whole at CAD 500 million or CAD 5.85 per share. This is based on a risk-adjusted net present value analysis of income from RVX-208. RVX-208 clearly has blockbuster potential. We choose not to value the company’s total technology platform and potential additional indications for RVX-208 and therefore only to make a valuation of the current clinical pipeline of RVX-208. We feel that potential value of its platform and additional indications offers an additional upside potential. With the start of a large Phase III clinical trial we estimate a probability of success of 54%. This is based on an independent survey executed by BioMedTracker and BIO in 20121. See also the graph below.
As noted earlier we believe that with a successful Phase III BETonMACE trial, efficient NNT to reduce MACE events, and considering the market potential for RVX-208 the upside pipeline potential for Resverlogix should be in line with earlier reported agents such as CETP with bull case model reporting up to $10 Billion in revenue potential, Deutsche Bank 2012 Report.
14. SWOT Analysis
Strengths Strong patent position with its lead compound RVX-208 Significant scarcity value – 8-9 lead in BET inhibition (no known BET competitor) Strong management and human therapy development expertise Novel and highly differentiated approach to impacting residual risk in diabetes and CKD Vast expertise in CVD, diabetes and neurodegenerative disease Sufficient access to finance its clinical program with RVX-208
Weaknesses Ongoing liver safety analysis for new BET therapeutic class Operating losses cumulating year-on-year Delay pipeline development RVX-208
Opportunities Profitable Partnerships and license agreements with large pharmaceuticals Blockbuster potential RVX-208 Favourable early pharmacoeconomics modeling with RVX-208
Threats Uncertainty about the outcome of clinical trial of the products Higher level of expenditure than budgeted Potential ongoing clinical trials needed in CVD
16. Management Capabilities
Resverlogix is led by seasoned biotechnology innovators. The company is led by an experienced Board and management team, which has been responsible for the rapid development of the business and has a successful track record of developing, protecting and commercializing innovative scientific products and processes. In the past several years, Resverlogix has been investing in developing a team of experts that have a focus on patient outcomes and can deliver results. Its board and senior management team are highly experienced in the development and early stage commercialisation of therapeutics for cardiovascular disease.
Management Team Donald McCaffrey, Chief Executive Officer Donald McCaffrey is Co-Founder, President, & CEO of Resverlogix Corp. He has over 30 years of experience in drug discovery & development, and international conference and tradeshowmanagement across multiple industries, including biotechnology. Don has led Resverlogix through significant change and achievement from its initial days as a private company to becoming a TSX listed company, including raising over CAD 185 million. In addition to garnering appropriate financing for Resverlogix’s aggressive development plan, Don has strategically directed the Company in its discussions with top global pharmaceutical companies, while creating new therapeutic markets for its key technology platforms. Don’s expertise in corporate operations has attracted an international team of R&D experts to Resverlogix. This scientific and operational expertise has pioneered RVX-208, a drug which has the potential to be first in a new class of drugs for the treatment of cardiovascular disease. Under his guidance Resverlogix has won multiple awards including the 2008 WEF Technology Pioneer award.
RESVERLOGIX 53 Dr Norman Wong, Chief Scientific Officer Dr. Wong's research interest focus is on the molecular actions of hormones related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus. His clinical interest encompasses patients with thyroid disease or diabetes mellitus. His most recent successes have come from elucidating the potential therapeutic opportunities for cardiovascular disease by harnessing the regulation of Apolipoprotein A-I (ApoA-I) gene expression. Dr. Wong keeps active in the academic community with speaking engagements at national and international medical conferences. He has been the author and co-author of more than 275 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.
Dr. Jan O. Johansson, M.D., PH.D. Senior Vice President Medical Affairs Dr. Johansson has had a distinguished 30 plus year career of which the past 18 years have been in small biotechnology and large pharmaceutical companies with expertise in the cardiovascular disease therapeutic area. He has served as Chief Medical Officer at Nuvelo, Inc., VP, Clinical Research and Development at Lipid Sciences, Inc. and was Co-founder, VP, Clinical Affairs and Senior Clinical Research Fellow of Esperion Therapeutics, Inc. From 1995 to 1997, Dr. Johansson was a medical adviser with executive responsibilities at Pharmacia bringing one lipid lowering product to the market and heading the apolipoprotein A-I Milano clinical program. Dr.Johanssonearned his M.D. and Ph.D. at the Karolinska Institute inSwedenwhere he lead a successful career as a tenured associate professor at the Karolinska Hospital and as a practicing physician. He has published more than 50 peer-review medical articles, and is a member of several scientific
54 RESVERLOGIX organizations including the American Heart Association and the European Atherosclerosis Society.
Dr. Michael Sweeney M.D. Senior Vice President Clinical Development Dr. Sweeney, a cardiologist with extensive experience in pharmaceutical product development and marketing, will oversee clinical development programs for RVX- 208 in cardiovascular disease (CVD), diabetes mellitus, and other indications. Dr. Sweeney has an impressive career history, spanning over 26 years in the pharmaceutical industry. This includes 11 years at Pfizer Inc., holding a variety of senior-level medical and marketing positions, including Senior Director, Urology Global Medical Group Leader and Director of Marketing of the Viagra® Worldwide Team. Prior to joining Resverlogix, Dr. Sweeney was Chief Medical Officer and Vice President of Research and Development at Depomed, Inc. in Silicon Valley. Dr. Sweeney was also the Vice President of Medical Affairs at CV Therapeutics, Inc., where he built the medical affairs department to enable the successful launch of Ranexa® for patients with cardiovascular disease and chronic angina.
Kenneth Lebioda BA. Senior Vice President Business Corporate Development Ken has over 25 years experience in the innovative pharmaceutical industry with leading global companies such as Bristol-Myers Squibb, Hoechst Marion Roussel and Marion Merrell Dow. He held a variety of management positions with these companies in the areas of sales and business development, regulatory affairs, reimbursement and market access. Ken's past contributions helped build multiple billion dollar leading global cardiovascular brands such as Plavix, Pravachol, Cardizem, and Avapro. Ken will provide strategic guidance for the company's technologies in the areas of market analysis, product positioning, regulatory affairs, key opinion leader outreach, pharmacoeconomics,licensing and commercial development.
RESVERLOGIX 55 Brad Cann, Chief Financial Officer Brad has more than 19 years of financial and business experience. Prior to joining Resverlogix, Brad was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust, a diversified hospitality trust engaged in hotel ownership, investment, management and franchising, and Canada's second largest hotel REIT. Brad joined Royal Host in January 2004 and held a number of senior positions and was appointed Chief Financial Officer in May 2007 and Executive Vice President in January 2008. Brad's responsibilities included financial reporting, accounting, taxation, investor relations, payroll, information technology and internal audit. As acting Co-Chief Executive Officer of Royal Host, Brad shared responsibility for developing the strategic initiatives of the Trust and leading its executive team in day-to-day operations, as well as investing, financing and real estate transactions. Prior to joining Royal Host, Brad was a business consultant and held senior management positions with several companies including Chief Financial Officer of a sulphur export development company and Chief Financial Officer of an oilfield waste water treatment company. Prior thereto, Brad held various positions with a chartered accounting firm.